Clinic
Palmetto Infusion Services LLC
Palmetto Infusion Services LLC was paid $93.59M by Medicaid between Jan 2018 and Dec 2024, across 42 billing codes. Its largest line is J2350, Injection, ocrelizumab, 1 mg — 26% of everything it billed.
33Billing provider infoPALMETTO INFUSION SERVICES LLC
WEST COLUMBIA, SC 29169
WEST COLUMBIA, SC 29169
33aNPI1265462659assigned 07/03/2006
33bProvider typeClinic/Center
28Total paid$93.59M
24GClaims116,428
24DCodes billed42
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinic/Center providers in South Carolina
Rank by total paid#1 of 33
Median peer was paid$154K
This provider vs. median607×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 8,903 | $6.73M | |
| 2019 | 12,293 | $9.66M | |
| 2020 | 14,583 | $14.73M | |
| 2021 | 17,727 | $14.58M | |
| 2022 | 20,881 | $17.80M | |
| 2023 | 22,084 | $17.43M | |
| 2024incomplete | 19,957 | $12.68M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J2350 | Injection, ocrelizumab, 1 mg | 26% | 1,760 | 1,552 | $24.46M |
| J2357 | Injection, omalizumab, 5 mg | 13% | 12,353 | 6,604 | $12.09M |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 12% | 8,320 | 5,712 | $10.85M |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 9.4% | 1,904 | 1,795 | $8.82M |
| J2323 | Injection, natalizumab, 1 mg | 8.0% | 2,687 | 2,453 | $7.53M |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 6.9% | 4,018 | 1,687 | $6.50M |
| J0490 | Injection, belimumab, 10 mg | 4.7% | 3,482 | 1,822 | $4.37M |
| J9312 | Injection, rituximab, 10 mg | 2.9% | 586 | 420 | $2.74M |
| Q5121 | Injection, infliximab-axxq, biosimilar, (avsola), 10 mg | 2.6% | 2,060 | 1,091 | $2.40M |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 2.5% | 1,446 | 403 | $2.36M |
| J0517 | Injection, benralizumab, 1 mg | 2.3% | 963 | 916 | $2.16M |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 2.3% | 1,161 | 548 | $2.12M |
30 more codes
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | 2.1% | 2,889 | $1.96M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.3% | 14,377 | $1.19M |
| J2182 | Injection, mepolizumab, 1 mg | 1.1% | 648 | $1.03M |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | <1% | 444 | $645K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 8,081 | $399K |
| S9500 | Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem | <1% | 6,486 | $263K |
| 96401 | <1% | 5,111 | $239K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 5,352 | $224K |
| 96415 | <1% | 8,374 | $215K | |
| J9310 | Injection, rituximab, 100 mg | <1% | 41 | $179K |
| J2356 | Injection, tezepelumab-ekko, 1 mg | <1% | 98 | $178K |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | <1% | 102 | $139K |
| J3032 | Injection, eptinezumab-jjmr, 1 mg | <1% | 68 | $129K |
| J0897 | Injection, denosumab, 1 mg | <1% | 419 | $123K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,541 | $83K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 124 | $55K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,427 | $33K |
| J0491 | Injection, anifrolumab-fnia, 1 mg | <1% | 12 | $28K |
| S9501 | Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 12 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem | <1% | 577 | $27K |
| J3262 | Injection, tocilizumab, 1 mg | <1% | 35 | $23K |
| S9502 | Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem | <1% | 509 | $17K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 9,065 | $7K |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 807 | $3K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,689 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 660 | $3K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,357 | $3K |
| J1750 | Injection, iron dextran, 50 mg | <1% | 14 | $3K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 56 | $557.96 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 12 | $238.18 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 313 | $162.15 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARTLEY, CONNIE (VICE PRESIDENT REIMBURSEMENT)
| Provider | Location | Paid |
|---|---|---|
| Palmetto Infusion Services, LLC | Florence, SC | $16K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.